In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested. 

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.

The research focused on a radiopharmaceutical that contains the isotope zirconium 89, which has a significantly longer half-life compared to gallium-68-labelled PSMA ligands.

For 47% of patients with long COVID symptoms, brain PET scans identified mild to moderate or severe hypometabolic patterns. 

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression. 

A new analysis in Brain, Behavior, and Immunity shows that no one is immune to the effects of the ongoing pandemic.